FDA Approves Tiziana Life Sciences Phase 2 IND for Multiple System Atrophy
MWN-AI** Summary
On August 11, 2025, Tiziana Life Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for the Phase 2a clinical trial of its lead candidate, intranasal foralumab, in treating patients with Multiple System Atrophy (MSA). MSA is a severe neurodegenerative disorder characterized by autonomic dysfunction and motor impairment, with no current FDA-approved therapies. This milestone represents a significant advancement for patients suffering from this orphan disease, which has a poor prognosis and median survival of only 6 to 9 years.
The Phase 2a trial is an open-label, six-month study aimed at assessing the effects of intranasal foralumab on microglial activation, alongside clinical outcomes and safety in MSA patients. Intranasal foralumab, a fully human anti-CD3 monoclonal antibody, is intended to target T-cell mediated neuroinflammation, a key factor in MSA progression. The administration involves eight three-week dosing cycles via nasal spray.
Dr. Vikram Khurana, a prominent figure in the MSA research field, expressed enthusiasm for the FDA's approval, highlighting the drug's potential to significantly influence immune activation in the brain and slow progression of the disease. Ivor Elrifi, CEO of Tiziana, added that foralumab's mechanism to induce regulatory T cells may offer a promising approach in treating neuroinflammatory and degenerative conditions not only limited to MSA but extending to diseases like Multiple Sclerosis and Alzheimer’s.
As one of the few fully human anti-CD3 monoclonal antibodies in clinical development, intranasal foralumab signifies Tiziana's innovative strategy to improve immunotherapy's efficacy and safety through non-systemic delivery methods, broadening its potential therapeutic applications in future pipelines.
MWN-AI** Analysis
Tiziana Life Sciences (NASDAQ: TLSA) has recently marked a significant milestone with the FDA’s approval of its IND for a Phase 2a clinical trial of intranasal foralumab, targeting the debilitating condition of Multiple System Atrophy (MSA). This approval is pivotal, as MSA lacks FDA-approved treatments and poses a challenging landscape for affected patients and their families.
For investors, this news is a double-edged sword; while the approval highlights Tiziana's innovative approach to neuroinflammation and potential to capture a niche market, the inherent risks associated with clinical trials remain substantial. MSA, classified as an orphan disease, affects approximately 3 to 5 per 100,000 in older adults but presents significant growth opportunities given the urgent unmet medical need. Investors should weigh the potential sales for foralumab, should trials succeed, against the uncertainties tied to clinical outcomes and eventual market entry.
Tiziana's approach with intranasal foralumab is distinctive—utilizing a non-systemic method to induce regulatory T cells and modulate inflammation, which may appeal to investors seeking groundbreaking biopharmaceutical advancements. The company has also indicated promising preliminary findings in its cohort of non-active Secondary Progressive Multiple Sclerosis patients, enhancing its value proposition.
However, market players must closely monitor trial developments and publication of results. The stock may experience volatility in response to interim findings or competitive news in the biotech realm. As a best practice, consider a diversified investment strategy to hedge against potential setbacks in clinical trials while tracking Tiziana’s advancements carefully. In conclusion, Tiziana presents an intriguing opportunity, particularly as it seeks to address a significant gap in MSA treatments, but traditional caution in biotech investing should be exercised.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, is pleased to announce that the U.S. Food & Drug Administration (FDA) have approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA). Multiple System Atrophy is an unmet medical need as there are currently no FDA approved therapies to treat this life limiting, orphan designated disease.
The Phase 2a study (ClinicalTrials.gov Identifier: NCT06868628 ) is a six?month, open?label clinical trial designed to evaluate the effects of intranasal foralumab on microglial activation, clinical outcomes, and safety in MSA patients. Foralumab, a fully human anti-CD3 monoclonal antibody targets T?cell mediated neuroinflammation and is administered via nasal spray in eight 3?week dosing cycles.
Multiple System Atrophy is an orphan disease, with a mean incidence in the US of 0.6:100,000 person-years, increasing with ?50 years of age to 3:100,000 person-years. Prevalence estimates for MSA range from 1.9-4.9 per 100,000 worldwide, suggesting that environmental, genetic, and epigenetic influences contribute to disease pathogenesis. MSA is a rapidly progressive neurodegenerative disorder affecting autonomic functions (such as blood pressure, bladder control) and motor control, leading to severe disability and shortened life expectancy. Increasing evidence implicates neuroinflammation and microglial activation as key drivers in MSA pathogenesis, contributing to neuronal degeneration. Disease progression is assessed using the unified MSA rating scale (UMSARS), which rates activities of daily life, autonomic and motor impairment, as well as overall disability. Disease prognosis is poor with a median survival of 6-9 years.
“We are pleased that the FDA have approved the IND to treat MSA patients with nasal foralumab,” said Vikram?Khurana, MD, PhD, Tracy T. Batchelor Endowed Chair in Neurology, and Division Chief of Movement Disorders and Director of the MSA Center of Excellence at Brigham and Women’s Hospital and Principal Investigator of the MSA trial. “Neuroinflammation plays a significant role in MSA’s rapid progression. Intranasal foralumab offers a novel therapeutic pathway by targeting T-cell mediated immune activation in the brain. We aim to observe whether this therapy can meaningfully impact microglial activity and important clinical outcomes over six months in patients with MSA.”
Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences commented on the rationale of foralumab for the treatment of MSA; “Foralumab administered intranasally induces regulatory T cells and modulates T-cell-driven inflammation. Its ability to reduce microglial activation presents a promising therapeutic strategy to slow neuronal damage in neuroinflammatory and degenerative diseases such as Multiple Sclerosis, Alzheimer’s Disease, ALS, and MSA. This novel, non-systemic approach is designed to engage regulatory T cells, promoting immune tolerance while minimizing systemic immune suppression.”
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ**
How does Tiziana Life Sciences plc TLSA plan to assess the clinical outcomes of intranasal foralumab in the Phase 2a study for MSA, particularly regarding microglial activation and safety over the six-month trial period?
What unique advantages does Tiziana Life Sciences plc TLSA believe intranasal foralumab offers over conventional therapies for neurodegenerative diseases like Multiple System Atrophy (MSA)?
Can you detail the strategy of Tiziana Life Sciences plc TLSA in targeting regulatory T cells with foralumab and how it aims to minimize systemic immune suppression while addressing neuroinflammation in MSA?
What are the anticipated milestones for Tiziana Life Sciences plc TLSA in the ongoing clinical trials of foralumab, including the timing for potential results from both the MSA and non-active SPMS studies?
**MWN-AI FAQ is based on asking OpenAI questions about Tiziana Life Sciences plc (NASDAQ: TLSA).
NASDAQ: TLSA
TLSA Trading
1.64% G/L:
$1.24 Last:
18,443 Volume:
$1.23 Open:
